Non-vitamin K antagonist oral anticoagulants (NOACs) - direct oral anticoagulants - are getting the ever-broadening use in clini- cal practice. However, many problems related to optimal use of NOACs in specific clinical situations remain unresolved. European Heart Rhythm Association in April 2018 issued the renovated recommendations on the use of NOACs in patients with atrial fibril- lation. The authors of recommendations presented some specific clinical variants for which they formulated practical advices based on the evidence obtained in randomized clinical trials. They also outlined the indications for use of NOACs, formulated practical start-program and scheme of subsequent follow-up management of patients taking NOACs. Recommendations contain information on pharmacokinetics of NOACs and their interactions with other drugs, consideration of feasibility of NOACs use in patients with chronic renal insufficiency or advanced liver disease. Many other practical problems are covered as well.
CITATION STYLE
Popova, L. V., Kondratieva, T. B., Aksenova, M. B., Khlevchuk, T. V., & Kanevskaya, M. Z. (2019). Recommendations on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (based on 2018 European heart rhythm association practical guide). Kardiologiya. Limited Liability Company KlinMed Consulting. https://doi.org/10.18087/CARDIO.2019.5.2633
Mendeley helps you to discover research relevant for your work.